Kaken Pharmaceutical Co (TSE:4521) Marketable Securities: 円5,992 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4521 Kaken Pharmaceutical Co Ltd TSE:4521
62 GF Score
Price 円3,980.00
GF Value 円3,992.67
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Kaken Pharmaceutical Co Marketable Securities?

Kaken Pharmaceutical Co TSE:4521 -0.13% 62 Marketable Securities is 円5,992 Mil as of Mar. 2026. GuruFocus rates TSE:4521 with a GF Score™ of 62/100 and a GF Value™ of 円3,992.67 (Fairly Valued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Kaken Pharmaceutical Co's Marketable Securities for the quarter that ended in Mar. 2026 was 円5,992 Mil.

Kaken Pharmaceutical Co's annual Marketable Securities increased from Mar. 2024 (円14,699 Mil) to Mar. 2025 (円15,992 Mil) but then declined from Mar. 2025 (円15,992 Mil) to Mar. 2026 (円5,992 Mil).

Kaken Pharmaceutical Co  (TSE:4521) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Kaken Pharmaceutical Co Marketable Securities Related Terms

Kaken Pharmaceutical Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Kaken Pharmaceutical Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaken Pharmaceutical Co Marketable Securities Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13,599.00 14,699.00 14,699.00 15,992.00 5,992.00

Kaken Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15,992.00 11,992.00 11,988.00 8,991.00 5,992.00
TSE:4521
62GF Score
Kaken Pharmaceutical Co Ltd TSE:4521
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kaken Pharmaceutical Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of 円5,992 Mil mean?
Kaken Pharmaceutical Co (TSE:4521) has a Marketable Securities of 円5,992 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Marketable Securities too high?
Kaken Pharmaceutical Co's current Marketable Securities is 円5,992 Mil. Overall, Kaken Pharmaceutical Co has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Marketable Securities compare to ZTS?
Kaken Pharmaceutical Co's Marketable Securities of 円5,992 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Marketable Securities is 円5,992 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,992.67, compared to a current price of 円3,980.00 — trading 0.3% below its estimated fair value. The current Marketable Securities is 円5,992 Mil. Kaken Pharmaceutical Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Marketable Securities is 円5,992 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?

Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be undervalued. The current stock price of 円3,980.00 is trading 0.3% below its estimated GF Value™ of 円3,992.67. GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4521:

  • Marketable Securities: 円5,992 Mil
  • GF Value™: 円3,992.67 vs. price of 円3,980.00 (0.3% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kaken Pharmaceutical Co Business Description

Address 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
62GF Score

Get the complete analysis for TSE:4521

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,980.00
Price
円3,992.67
GF Value